It would be hard to deny the potential that exists for OncoSec Medical (OTCBB: ONCS) as the biopharmaceutical company focusing on the development of advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease holds the inside edge on a potentially revolutionary method of administering both chemotherapy and immunotherapy agents as a means of fighting cancer.
With three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers currently in the works ONCS has certainly put themselves in a position to attract investor attention yet the company’s share price remains relatively low. Just last month shares hit a low of 0.1650 and in May they were as low as 0.1450 and while they have climbed as high as 0.2980 since that time they are currently moving around the 0.2530 level, a price that would look like a bargain if they manage to see their clinical trials through FDA approval.
What may be frightening to some investors is the fact that ONCS has essentially placed all their eggs in one basket, that being electroporation which can dramatically improve the permeability of a patient’s cell membrane and subsequently allow for an exponential increase in the uptake of an administered drug. Additionally, electroporation delivery technique is advantageous over other delivery techniques in that it has minimal carrier issues and is cost effective for the patient.
The electroporation technology implemented by ONCS comes from a license agreement the biopharmaceutical company struck with Inovio in March 2011 and since renamed OMS ElectroImmunotherapy and OMS ElectroChemotherapy to better reflect its use in cancer treatments.
As it stands ONCS’s ElectroImmunotherapy platform has Phase II interim data for metastatic melanoma, Phase II interim data for Merkel cell carcinoma and enrollment initiation for a Phase II trial for the treatment of cutaneous T-cell lymphoma all expected by the end of the year. Coming sooner will be Phase III data for its OMS ElectroChemotherapy for Head and Neck Cancer which is expected later this month.
Essentially what ONCS is doing is creating a more effective method of treating cancer by enhancing the efficiency with which agents can be delivered to cancer patients. ONCS has pointed out that their OncoSec Medical System (OMS) dramatically enhances “the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy).”
Currently ONCS using two different types of agents in their clinical trials those being interlukin-12 (IL-12) with the ElectroImmunotherapy platform, and bleomycin as the agent for ElectroChemotherapy. It should be noted that other agents could be substituted, opening the door to even more potential treatments for cancer.
According to ONCS the therapies they are advancing “address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.”
Having already demonstrated their OMS ElectroImmunotherapy platform to be safe and well tolerated in Phase I data ONCS could be on the path for substantial gains if their Phase II interim updates demonstrate efficacy. The same holds true for their ElectroChemotherapy platform and data from that Phase III trial for Head and Neck Cancer should be coming shortly.
Obviously there is still a risk involved with ONCS and with everything apparently riding on what they have going right now and limited finances the company could fall apart if the results aren’t favorable. Even so, with a current share price that favors a risk the rewards could be massive for those investors who got in before the good news hit.